Vivanza Biosciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• Vivanza Biosciences Ltd reported a 85.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1101.9%.
• Its expenses for the quarter were down by 85.2% QoQ and up 339.5% YoY.
• The net profit decreased 325.0% QoQ and decreased 55.0% YoY.
• The earnings per share (EPS) of Vivanza Biosciences Ltd declined at 0.11 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Vivanza Biosciences Ltd is a company operating in the biosciences sector, which typically involves research, development, and commercialization of products related to healthcare and biotechnology. The specific products or services offered by Vivanza Biosciences Ltd are not detailed in the provided data, nor are there any recent major developments listed. Companies in this industry often focus on innovative solutions in medical research and drug development. However, without additional information, the exact nature of Vivanza Biosciences Ltd’s business activities remains unspecified.

Revenue

In Q4FY26, Vivanza Biosciences Ltd reported a total income of ₹6.37 crores. This marks a significant quarter-over-quarter (QoQ) decrease of 85.9% from ₹45.33 crores in Q3FY26. Year-over-year (YoY), the total income increased substantially by 1101.9% from ₹0.53 crores in Q4FY25. Such fluctuations in total income are noteworthy, reflecting substantial changes in the company’s revenue-generating activities over the periods compared.

Profitability

The profitability metrics for Vivanza Biosciences Ltd show a challenging financial period in Q4FY26. The company reported a loss before tax of ₹0.30 crores, a decline from a profit of ₹0.20 crores in Q3FY26, representing a 250.0% decrease QoQ. The YoY comparison shows an improvement of 69.7% from a loss of ₹0.99 crores in Q4FY25. The tax expense was ₹0.15 crores in Q4FY26, up significantly by 1400.0% YoY from ₹0.01 crores in Q4FY25. The profit after tax was a loss of ₹0.45 crores in Q4FY26, down by 325.0% QoQ from a profit of ₹0.20 crores in Q3FY26, but improved by 55.0% YoY from a loss of ₹1.00 crores in Q4FY25. The earnings per share (EPS) was negative at ₹-0.11, showing a decline QoQ from ₹0.05 and a YoY improvement from ₹-0.25.

Operating Metrics

Vivanza Biosciences Ltd's total expenses in Q4FY26 amounted to ₹6.68 crores, which is a significant decrease of 85.2% QoQ from ₹45.13 crores in Q3FY26. However, compared to the previous year, there is a 339.5% increase from ₹1.52 crores in Q4FY25. This indicates considerable variability in operating costs, which may relate to changes in operational scale or cost management strategies. The company's operating performance metrics, reflected in the reported financial results, highlight significant changes in both income and expenses over the past year and quarter, suggesting dynamic operational conditions.